Cite
HARVARD Citation
Chen, C. et al. (2019). A phase 2 study of ofatumumab (Arzerra®) in combination with a pan-AKT inhibitor (afuresertib) in previously treated patients with chronic lymphocytic leukemia (CLL)*. Leukemia & lymphoma. 60 (1), pp. 92-100. [Online].